TrialNature medicine2022

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.

Nazli Dizman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.